AI summary · may contain errors
In relapsed or refractory multiple myeloma, talquetamab plus daratumumab with pomalidomide improved progression-free survival versus daratumumab plus pomalidomide and dexamethasone, with 24-month estimates of 81.3% and 77.6%.
- 1 cited this week
